Home
/
Altimmune, Inc.
/
Financials
/
Quarterly
Altimmune, Inc. — Quarterly Financials
Quarterly figures from SEC EDGAR XBRL filings (10-Q)
These figures are extracted from XBRL-tagged quarterly reports (10-Q) that Altimmune, Inc. filed with the SEC. Values are as reported for each individual quarter (Q1, Q2, Q3, Q4) — not cumulative year-to-date. Negative figures indicate a loss.
Revenue — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
$5.0K
Nov 6, 2025
Q2
2025
Jun 30, 2025
$5.0K
Aug 12, 2025
Q1
2025
Mar 31, 2025
$5.0K
May 13, 2025
Q3
2025
Sep 30, 2024
$5.0K
Nov 6, 2025
Q2
2025
Jun 30, 2024
$5.0K
Aug 12, 2025
Q1
2025
Mar 31, 2024
$5.0K
May 13, 2025
Q3
2024
Sep 30, 2023
$362.0K
Nov 12, 2024
Q2
2024
Jun 30, 2023
$6.0K
Aug 8, 2024
Q1
2024
Mar 31, 2023
$21.0K
May 9, 2024
Q3
2023
Sep 30, 2022
$2.0K
Nov 7, 2023
Q2
2023
Jun 30, 2022
$8.0K
Aug 10, 2023
Q1
2023
Mar 31, 2022
$32.0K
May 11, 2023
Revenue — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2022
Sep 30, 2022
$2.0K
Nov 10, 2022
Q2
2022
Jun 30, 2022
$8.0K
Aug 11, 2022
Q1
2022
Mar 31, 2022
$32.0K
May 12, 2022
Q3
2022
Sep 30, 2021
$158.0K
Nov 10, 2022
Q2
2022
Jun 30, 2021
$137.0K
Aug 11, 2022
Q1
2022
Mar 31, 2021
$838.0K
May 12, 2022
Q3
2021
Sep 30, 2020
$2.94M
Nov 9, 2021
Q2
2021
Jun 30, 2020
$721.6K
Aug 10, 2021
Q1
2021
Mar 31, 2020
$2.21M
May 17, 2021
Q3
2020
Sep 30, 2019
$644.0K
Nov 9, 2020
Q2
2020
Jun 30, 2019
$1.63M
Aug 11, 2020
Q1
2020
Mar 31, 2019
$2.96M
May 13, 2020
Q3
2019
Sep 30, 2018
$2.63M
Nov 13, 2019
Q2
2019
Jun 30, 2018
$2.42M
Aug 13, 2019
Q1
2019
Mar 31, 2018
$2.69M
May 14, 2019
Q3
2018
Sep 30, 2017
$4.59M
Nov 13, 2018
Q2
2018
Jun 30, 2017
$3.04M
Aug 14, 2018
Revenue (Net Sales) — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q1
2018
Mar 31, 2018
$2.69M
May 15, 2018
Q3
2017
Sep 30, 2017
$4.59M
Nov 9, 2017
Q2
2017
Jun 30, 2017
$3.04M
Aug 14, 2017
Q1
2018
Mar 31, 2017
$299.6K
May 15, 2018
Q3
2017
Sep 30, 2016
$901.0K
Nov 9, 2017
Q2
2017
Jun 30, 2016
$746.0K
Aug 14, 2017
Net Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
($19.01M)
Nov 6, 2025
Q3
2025
Jun 30, 2025
($22.15M)
Nov 6, 2025
Q2
2025
Jun 30, 2025
($22.15M)
Aug 12, 2025
Q1
2025
Mar 31, 2025
($19.58M)
May 13, 2025
Q3
2025
Mar 31, 2025
($19.58M)
Nov 6, 2025
Q2
2025
Mar 31, 2025
($19.58M)
Aug 12, 2025
Q3
2025
Sep 30, 2024
($22.85M)
Nov 6, 2025
Q3
2025
Jun 30, 2024
($24.64M)
Nov 6, 2025
Q2
2025
Jun 30, 2024
($24.64M)
Aug 12, 2025
Q2
2025
Mar 31, 2024
($24.39M)
Aug 12, 2025
Q1
2025
Mar 31, 2024
($24.39M)
May 13, 2025
Q3
2025
Mar 31, 2024
($24.39M)
Nov 6, 2025
Q3
2024
Sep 30, 2023
($20.67M)
Nov 12, 2024
Q2
2024
Jun 30, 2023
($16.06M)
Aug 8, 2024
Q3
2024
Jun 30, 2023
($16.06M)
Nov 12, 2024
Q1
2024
Mar 31, 2023
($20.07M)
May 9, 2024
Q3
2024
Mar 31, 2023
($20.07M)
Nov 12, 2024
Q2
2024
Mar 31, 2023
($20.07M)
Aug 8, 2024
Q3
2023
Sep 30, 2022
($23.52M)
Nov 7, 2023
Q3
2023
Jun 30, 2022
($20.11M)
Nov 7, 2023
Operating Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
($20.86M)
Nov 6, 2025
Q2
2025
Jun 30, 2025
($22.92M)
Aug 12, 2025
Q1
2025
Mar 31, 2025
($21.82M)
May 13, 2025
Q3
2025
Sep 30, 2024
($24.77M)
Nov 6, 2025
Q2
2025
Jun 30, 2024
($26.75M)
Aug 12, 2025
Q1
2025
Mar 31, 2024
($26.79M)
May 13, 2025
Q3
2024
Sep 30, 2023
($22.54M)
Nov 12, 2024
Q2
2024
Jun 30, 2023
($18.01M)
Aug 8, 2024
Q1
2024
Mar 31, 2023
($21.76M)
May 9, 2024
Q3
2023
Sep 30, 2022
($24.75M)
Nov 7, 2023
Q2
2023
Jun 30, 2022
($20.40M)
Aug 10, 2023
Q1
2023
Mar 31, 2022
($19.50M)
May 11, 2023
Q3
2022
Sep 30, 2021
($33.20M)
Nov 10, 2022
Q2
2022
Jun 30, 2021
($24.86M)
Aug 11, 2022
Q1
2022
Mar 31, 2021
($14.86M)
May 12, 2022
Q3
2021
Sep 30, 2020
($18.32M)
Nov 9, 2021
Q2
2021
Jun 30, 2020
($18.42M)
Aug 10, 2021
Q1
2021
Mar 31, 2020
($7.31M)
May 17, 2021
Q3
2020
Sep 30, 2019
($11.27M)
Nov 9, 2020
Q2
2020
Jun 30, 2019
($3.55M)
Aug 11, 2020